Becton Dickinson and Co (BDX)
Fair ValueFundamental
60
Price
$178.34
Market Cap
$50.07B
Part 1 · What the company is worth
Overview
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on September 18, 2026 with claude-haiku-4-5 — shared with all users
Baxter sells infusion pumps, IV sets and injectable drug delivery systems to the same hospital pharmacies and purchasing groups that buy BD's medication delivery and infusion business.
After absorbing Hospira's infusion business, ICU Medical bids against BD for hospital contracts on infusion pumps, IV sets and vascular access consumables.
Abbott competes with BD's Life Sciences arm for hospital laboratory budgets, supplying diagnostic instruments and infectious-disease testing systems to the same clinical labs.
This family-owned German group competes with BD across the whole IV therapy line — catheters, infusion pumps, syringes and needles — in hospitals in Europe and the United States.
Teleflex competes head-on with BD's interventional and vascular access catalogue, above all central venous and PICC catheters bought by the same hospital departments.
Medtronic overlaps with BD on needles and syringes and on vascular and urology intervention devices sold to the same surgical and interventional specialists.
Balance Sheet & Liquidity
Revenue
$22.41B
Trailing 12 months (through 6/30/2026)
Net Income
$941M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$2.67B
Total Equity
$25.39B
Total Liabilities
$29.93B
Current Ratio
0.87
Interest Coverage
3.92
Debt/EBITDA
3.33
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$216.42
Current Price
$178.34
Margin of Safety
+17.6%
Fair Value Range
$140.67 - $292.17
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
54.08
ROE
6.6%
P/B Ratio
2.00
P/FCF
15.22
Gross Margin
46.7%
ROIC
4.4%
Profitability Radar
Value Creation (Economic Moat)
ROIC
4.4%
WACC
6.7%
ROIC − WACC
-2.3 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (17)
- EPS shows upward trend
- Gross Margin 46.7%
- P/FCF 15.22
- P/B Ratio 2.00
- Debt/Equity ratio
- Operating Margin 10.3%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Revenue Growth 5Y 6.3%
- Analyst Consensus 57% Buy
- Earnings Quality (OCF/NI) 4.20
- Share Dilution -0.9%
- Piotroski F-Score 8/9
Failed (10)
- EPS CAGR 2.88%
- Price CAGR 3.43%
- ROIC 4.4%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 3.8%
- Earnings Surprise avg 1.9%
- PEG Ratio 3.94
- Net Margin Trend 4.2% vs 8.0%
Unavailable (1)
- Dividend Payout NaN%
Piotroski F-Score
Strong financial health
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Buying back shares. Shareholder friendly
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Thomas E. Polen Jr. | President, CEO & Chairman | 52 |
| Dr. Michael D. Garrison | Executive VP & President of Medical Segment and BioPharma Systems Segments | 55 |
| Mr. Michael C. Feld | Executive VP & Chief Revenue Officer | 44 |
| Mr. Vitor Roque | Executive VP & CFO | 42 |
| Ms. Elizabeth McCombs | Executive VP & CTO | 48 |
| Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D. | Senior VP & Chief Scientific Officer | - |
| Ms. Denise Russell Fleming | Executive Vice President & Chief Information Officer | 54 |
| Mr. Shawn C. Bevec | Senior Vice President of Investor Relations | - |
| Ms. Lanesha T. Minnix J.D. | Executive VP & General Counsel | 50 |
| Carla Burigatto | Senior VP & Chief Communications Officer | - |
Audit Risk
3
Board Risk
6
Compensation Risk
5
Shareholder Rights Risk
1
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2025-11-25
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-08-06
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-08-06
via SEC EDGAR
Income History
via SEC EDGAR
Latest News
Recent headlines for BDX, sourced from Markets Gazette.